Three new investigational drugs have secured a place on the European Medicines Agency’s PRIME (priority medicines) scheme, including talquetamab and teclistamab, the bispecific antibodies that Janssen is developing to treat relapsed or refractory multiple myeloma.
ARU-1801, Aruvant Sciences’ one-time investigational gene therapy for sickle cell disease, is also among the latest product to win a...